Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker TVTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 78,400 | $55.02 | $4.3M Sale | Form 4 ↗ |
| Oct 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 37,270 | $54.20 | $2.0M Sale | Form 4 ↗ |
| Oct 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 128,065 | $52.97 | $6.8M Sale | Form 4 ↗ |
| Sep 17, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 8,282 | $65.07 | $538.9K Sale | Form 4 ↗ |
| Sep 17, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 6,802 | $64.95 | $441.8K Sale | Form 4 ↗ |
| Sep 17, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 101,691 | $64.59 | $6.6M Sale | Form 4 ↗ |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 79,113 | $63.65 | $5.0M Sale | Form 4 ↗ |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 93,604 | $63.25 | $5.9M Sale | Form 4 ↗ |
| Sep 16, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 96,125 | $63.64 | $6.1M Sale | Form 4 ↗ |
| Sep 16, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 99,716 | $63.26 | $6.3M Sale | Form 4 ↗ |
| Sep 16, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 47,746 | $63.61 | $3.0M Sale | Form 4 ↗ |
| Sep 16, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 65,104 | $63.12 | $4.1M Sale | Form 4 ↗ |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 400 | $65.31 | $26.1K Sale | Form 4 ↗ |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 1,900 | $63.69 | $121.0K Sale | Form 4 ↗ |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 20,735 | $62.61 | $1.3M Sale | Form 4 ↗ |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 27,473 | $62.00 | $1.7M Sale | Form 4 ↗ |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | TVTX Travere Therapeutics, Inc. | Sale | 400 | $65.31 | $26.1K Sale | Form 4 ↗ |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | TVTX Travere Therapeutics, Inc. | Sale | 1,600 | $63.69 | $101.9K Sale | Form 4 ↗ |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | TVTX Travere Therapeutics, Inc. | Sale | 17,284 | $62.62 | $1.1M Sale | Form 4 ↗ |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | TVTX Travere Therapeutics, Inc. | Sale | 25,390 | $62.02 | $1.6M Sale | Form 4 ↗ |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 300 | $63.66 | $19.1K Sale | Form 4 ↗ |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 800 | $62.85 | $50.3K Sale | Form 4 ↗ |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 4,275 | $62.14 | $265.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 1,431 | $65.31 | $93.5K Sale | Form 4 ↗ |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 1,400 | $63.65 | $89.1K Sale | Form 4 ↗ |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 27,421 | $62.59 | $1.7M Sale | Form 4 ↗ |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 71,938 | $62.05 | $4.5M Sale | Form 4 ↗ |
| Sep 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 270 | $65.31 | $17.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 3,102 | $63.64 | $197.4K Sale | Form 4 ↗ |
| Sep 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 28,796 | $62.66 | $1.8M Sale | Form 4 ↗ |
| Sep 15, 2026 | Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | TVTX Travere Therapeutics, Inc. | Sale | 63,498 | $61.99 | $3.9M Sale | Form 4 ↗ |
| Sep 15, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 270 | $65.31 | $17.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 3,000 | $63.65 | $190.9K Sale | Form 4 ↗ |
| Sep 15, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 29,021 | $62.66 | $1.8M Sale | Form 4 ↗ |
| Sep 15, 2026 | William E. Rote Chief Research Officer | TVTX Travere Therapeutics, Inc. | Sale | 63,907 | $61.99 | $4.0M Sale | Form 4 ↗ |
| Sep 15, 2026 | Elizabeth E. Reed Chief Legal Officer and GC | TVTX Travere Therapeutics, Inc. | Sale | 300 | $65.31 | $19.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Elizabeth E. Reed Chief Legal Officer and GC | TVTX Travere Therapeutics, Inc. | Sale | 1,400 | $63.69 | $89.2K Sale | Form 4 ↗ |
| Sep 15, 2026 | Elizabeth E. Reed Chief Legal Officer and GC | TVTX Travere Therapeutics, Inc. | Sale | 13,874 | $62.63 | $868.9K Sale | Form 4 ↗ |
| Sep 15, 2026 | Elizabeth E. Reed Chief Legal Officer and GC | TVTX Travere Therapeutics, Inc. | Sale | 21,926 | $62.03 | $1.4M Sale | Form 4 ↗ |
| Sep 10, 2026 | Jeffrey A. Meckler Director | TVTX Travere Therapeutics, Inc. | Sale | 3,100 | $68.09 | $211.1K Sale | Form 4 ↗ |
| Sep 10, 2026 | Jeffrey A. Meckler Director | TVTX Travere Therapeutics, Inc. | Sale | 14,000 | $67.46 | $944.4K Sale | Form 4 ↗ |
| Sep 10, 2026 | Jeffrey A. Meckler Director | TVTX Travere Therapeutics, Inc. | Sale | 1,200 | $66.15 | $79.4K Sale | Form 4 ↗ |
| Sep 10, 2026 | Jeffrey A. Meckler Director | TVTX Travere Therapeutics, Inc. | Sale | 1,700 | $65.39 | $111.2K Sale | Form 4 ↗ |
| Sep 2, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | TVTX Travere Therapeutics, Inc. | Sale | 642 | $66.37 | $42.6K Sale | Form 4 ↗ |
| Aug 18, 2026 | Gary A. Lyons Director | TVTX Travere Therapeutics, Inc. | Sale | 900 | $63.86 | $57.5K Sale | Form 4 ↗ |
| Aug 18, 2026 | Gary A. Lyons Director | TVTX Travere Therapeutics, Inc. | Sale | 4,100 | $63.27 | $259.4K Sale | Form 4 ↗ |
| Aug 17, 2026 | Gary A. Lyons Director | TVTX Travere Therapeutics, Inc. | Sale | 500 | $64.16 | $32.1K Sale | Form 4 ↗ |
| Aug 17, 2026 | Gary A. Lyons Director | TVTX Travere Therapeutics, Inc. | Sale | 2,600 | $63.50 | $165.1K Sale | Form 4 ↗ |
| Aug 17, 2026 | Gary A. Lyons Director | TVTX Travere Therapeutics, Inc. | Sale | 1,900 | $62.53 | $118.8K Sale | Form 4 ↗ |
| Jun 12, 2026 | Roy D. Baynes Director | TVTX Travere Therapeutics, Inc. | Sale | 4,500 | $50.00 | $225.0K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances